News and Events

Holiday closure of ReproCELL headquarters

ReproCELL headquarters in Japan closes on the dates below, for Japanese spring holiday season.

April 30th
May 3rd, 4th

US subsidiary and UK office won’t be affected, and will be operating as usual.

ReproCELL exhibits at BIO

ReproCELL will be exhibiting at BIO 2012 at Boston, MA.

BIO 2012
June 18-21, 2012 @ Boston, USA
Booth #1405 (in JETRO Japan pavilion)

Instruction movies for human iPSC culture procedure

Instruction movies for human iPS cell culture procedure are now available on our website.
http://www.reprocell.com/en/reagents/culture_movies/

ReproCELL exhibits at SLAS, SOT, ISSCR

GEN article introduced ReproCELL’s technology

ReproCELL’s iPS cell-derived cardiomyocytes, neurons and hepatocytes were introduced in Genetic Engineering & Biotechnology News (GEN).

Jan 15, 2012 (Vol. 32, No. 2)
Stem Cell Applications Hasten into the Clinic

Headquarters moved

ReproCELL headquarters has moved to a new address.

KDX Shin-Yokohama 381 Bldg. 9F
3-8-11,Shin-Yokohama,
Kohoku-ku, Yokohama
Kanagawa 222-0033,
Japan

The new office is located on the different floor of the same building as the previous one.

ReproFF2 Customer Feedback

Feedback comments and results from the customers using ReproFF2 are now available on our website.
ReproFF2 customer feedback

ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes – Expected Launch in Q2 2012

YOKOHAMA, Japan, December 15, 2011 – ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company licensed worldwide right to commercialize hepatocytes derived from human iPS (induced pluripotent stem) cells. ReproCELL has been collaborating with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan) to establish an effective in-vitro drug screening for hepatic toxicity and liver metabolism using hepatocytes derived from human iPS cells since early this year.

Together with NIBIO, the company successfully established the hepatocytes which highly express active drug metabolizing enzyme. Currently, the company is evaluating the system using various drugs with pharmaceutical companies to observe how the drugs are metabolized. ReproCELL is anticipating its commercialization in Q2 2012. Prior to the launch, sample of the cells will become available for testing to pharmaceutical and biotech companies in January 2012.

ReproCELL is a world-leading pioneer in commercializing human pluripotent stem cells as an effective tool for drug discovery and development. The company has successfully launched iPS cell derived cardiomyocytes in April 2009 for cardiac toxicity testing, followed by the launch of iPS cell derived neuronal cells in October 2010 for efficacy screening of neuroactive compounds.

ReproCELL’s Representative Director and CEO, Chikafumi Yokoyama PhD commented, “We are pleased to see iPS cell-derived hepatocytes showing the highest level of quality ever seen, expressing the same qualities as that of primary human hepatocytes currently used by the pharmaceutical industry, including drug metabolizing enzyme activity. We can expect to see its early adoption for drug toxicity and pharmacokinetic studies.”

Aspects of NIBIO’s technology on the induction of iPS cell-derived hepatocyte differentiation can be found in the following publication:

Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α Transduction.

Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A, Sakurai F, Hayakawa T, Kusuda Furue M, Mizuguchi H., Mol Ther. 2011 Nov 8. [Epub ahead of print] PMID: 22068426

Company: ReproCELL Inc. Representative: Chikafumi Yokoyama PhD,
Contact: info_repro@reprocell.com Tel：+81-(0)45-475-3887
KDX Shin-Yokohama 381 bldg. 8F, 3-8-11 Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa 222-0033, Japan

ReproHepato web page launched

Information about ReproHepato 3A4, a human iPSC-derived hepatocyte product, is now available on ReproCELL website. Updated information will be added continuously so please check the web page often. The product will be launched in Spring 2012.

ReproHepato 3A4 web page
Inquiry about ReproHepato 3A4

New Product: ReproCardio 2 (human iPSC-derived cardiomyocytes, frozen)

ReproCELL launches its second iPSC-cardiomyocyte product ReproCardio 2.
Since the world’s first launch of the first version product (ReproCardio), ReproCELL has been continuously improving the products and now established frozen cells as a product. ReproCardio 2 contains natural population of human heart cells which are necessary for efficient prediction of compound effects in the drug development process.
Please visit ReproCardio 2 product website to learn about it.

Page Top